BRIEF-US FDA Approves TREMFYA® (Guselkumab), The First And Only IL-23 Inhibitor Offering Both Subcutaneous And Intravenous Induction Options, For Adult Patients With Moderately To Severely Active Crohn's Disease

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

BRIEF-US FDA Approves TREMFYA® (Guselkumab), The First And Only IL-23 Inhibitor Offering Both Subcutaneous And Intravenous Induction Options, For Adult Patients With Moderately To Severely Active Crohn's Disease

, Reuters - 6:14 PM ET 3/20/2025 default

March 20 (Reuters) - Johnson & Johnson ( JNJ ):

* U.S. FDA APPROVES TREMFYA® (GUSELKUMAB), THE FIRST AND ONLY IL-23 INHIBITOR OFFERING BOTH SUBCUTANEOUS AND INTRAVENOUS INDUCTION OPTIONS, FOR ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE Source text: Further company coverage:

(c) Reuters 2025. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.